CRP and COVID-19: Thus, both the IDSA [25] and the ESCMID [21] recommend the use of tocilizumab among hospitalized adults with progressive severe (meaning needing oxygen) or critical COVID-19 (meaning patient patients on mechanical ventilation, on ECMO, or having end organ dysfunction as is seen in sepsis/septic shock), and who have elevated systemic inflammation markers (CRP > 75 mg/L).